Agenus Combo Shows Promise in Refractory Ovarian Cancer, Published in JITC
Event summary
- Agenus published clinical results in The Journal for ImmunoTherapy of Cancer (JITC) detailing the efficacy of botensilimab plus balstilimab (BOT+BAL) in a Phase 1b trial.
- The combination demonstrated a 23% overall response rate and a 31% clinical benefit rate in a heavily pretreated population of ovarian cancer patients.
- The median duration of response was 9.7 months, with a median overall survival of 14.8 months and 75% of patients alive at 12 months.
- The study enrolled 44 patients, with nearly three-quarters being platinum-resistant or platinum-refractory, a particularly challenging patient group.
The big picture
Ovarian cancer remains a significant unmet medical need, particularly for patients who have developed resistance to platinum-based chemotherapy. While checkpoint inhibitors have shown limited success, the data presented by Agenus suggest that combination immunotherapy approaches, particularly those leveraging novel mechanisms like botensilimab’s immune activation profile, may offer a meaningful improvement in outcomes for this patient population. The publication in JITC lends credibility to Agenus's approach and could attract further investment and partnerships.
What we're watching
- Regulatory Path
- The success of BOT+BAL in this difficult-to-treat population will likely accelerate discussions with regulatory bodies, but the relatively small sample size may necessitate larger trials for approval.
- Market Adoption
- The accessibility of BOT+BAL through early access programs, while beneficial for patients, could complicate commercialization strategies and impact pricing expectations.
- Competitive Landscape
- Given the limited efficacy of existing therapies, Agenus will need to demonstrate a clear and sustained advantage over emerging checkpoint inhibitor combinations to capture significant market share.
Related topics